Key Metrics
CiteScore 

8.1
Eigenfactor 

0.001 - 0.005
Impact Factor 

5 - 10
SJR 

Q2Oncology

SNIP 

1.39
Recommended pre-submission checks
Powered by 

Topics Covered on Experimental Hematology and Oncology
Experimental Hematology and Oncology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2590 | USD 2990 | GBP 2290 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in Experimental Hematology and Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Experimental Hematology and Oncology
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.
- 11 Jan 2026
- Experimental hematology & oncology
PRL-3 up-regulates exosomal ITGαvβ5 expression to promote liver pre-metastatic niche formation and colon cancer liver metastasis.
- 8 Jan 2026
- Experimental hematology & oncology
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
- 8 Jan 2026
- Experimental Hematology & Oncology
Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer
- 8 Jan 2026
- Experimental Hematology & Oncology
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma.
- 31 Dec 2025
- Experimental hematology & oncology
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy
- 31 Dec 2025
- Experimental Hematology & Oncology
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.
- 11 Jan 2026
- Experimental hematology & oncology
PRL-3 up-regulates exosomal ITGαvβ5 expression to promote liver pre-metastatic niche formation and colon cancer liver metastasis.
- 8 Jan 2026
- Experimental hematology & oncology
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
- 8 Jan 2026
- Experimental Hematology & Oncology
Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer
- 8 Jan 2026
- Experimental Hematology & Oncology
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma.
- 31 Dec 2025
- Experimental hematology & oncology
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy
- 31 Dec 2025
- Experimental Hematology & Oncology